Compare ATXG & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATXG | PMCB |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 6.6M |
| IPO Year | N/A | N/A |
| Metric | ATXG | PMCB |
|---|---|---|
| Price | $0.46 | $0.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 77.1K | ★ 3.0M |
| Earning Date | 11-14-2025 | 12-15-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | ★ $4,141,952.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $122.91 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.36 | $0.63 |
| 52 Week High | $1.86 | $1.90 |
| Indicator | ATXG | PMCB |
|---|---|---|
| Relative Strength Index (RSI) | 39.48 | 43.81 |
| Support Level | $0.45 | $0.63 |
| Resistance Level | $0.49 | $1.20 |
| Average True Range (ATR) | 0.03 | 0.13 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 74.74 | 21.93 |
Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services; Property management and subleasing. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.